2015 Pocket Guide for Asthma Management and Prevention
... infections, domestic or occupational allergens (e.g. house dust mite, pollens, cockroach), tobacco smoke, exercise and stress. These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g. beta-blockers, and (in some patients), aspirin or other NSAIDs. ...
... infections, domestic or occupational allergens (e.g. house dust mite, pollens, cockroach), tobacco smoke, exercise and stress. These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g. beta-blockers, and (in some patients), aspirin or other NSAIDs. ...
Pocket Guide for Asthma Management and Prevention 2015
... infections, domestic or occupational allergens (e.g. house dust mite, pollens, cockroach), tobacco smoke, exercise and stress. These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g. beta-blockers, and (in some patients), aspirin or other NSAIDs. ...
... infections, domestic or occupational allergens (e.g. house dust mite, pollens, cockroach), tobacco smoke, exercise and stress. These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g. beta-blockers, and (in some patients), aspirin or other NSAIDs. ...
Standard Treatment Guideline
... history of response to previous treatments, their family history of response to treatment, and their tolerance for different side effects; therefore, the expert’s first line recommendations may not be appropriate in all circumstances; however, several alternatives have been suggested to meet the req ...
... history of response to previous treatments, their family history of response to treatment, and their tolerance for different side effects; therefore, the expert’s first line recommendations may not be appropriate in all circumstances; however, several alternatives have been suggested to meet the req ...
Japanese guidelines for adult asthma 2017
... normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy diffe ...
... normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy diffe ...
Goal of the treatment
... mg/kg/d x 4 days) x 6 courses platelet count by day 7 > 50 x 104/L Splenectomy Introduced in 1916 Two thirds of patients achieve remission ineffective medical management or/and therapy associated toxicity ...
... mg/kg/d x 4 days) x 6 courses platelet count by day 7 > 50 x 104/L Splenectomy Introduced in 1916 Two thirds of patients achieve remission ineffective medical management or/and therapy associated toxicity ...
The Treatment of RLS and PLMD in Adults
... Flexible dose ropinirole (0.25-4.0 mg/day) or placebo. Medication titrated to an optimal dose, based on the investigator’s impression of individual efficacy and tolerability. Therapy was initiated at 0.25 mg/day of ropinirole or matching placebo for 2 days. At Day 2, the dose was then increased to 0 ...
... Flexible dose ropinirole (0.25-4.0 mg/day) or placebo. Medication titrated to an optimal dose, based on the investigator’s impression of individual efficacy and tolerability. Therapy was initiated at 0.25 mg/day of ropinirole or matching placebo for 2 days. At Day 2, the dose was then increased to 0 ...
Life Saving Drugs Programme Review: Technical Assessment
... Health Technology Assessment (AHTA) School of Population Health University of Adelaide ...
... Health Technology Assessment (AHTA) School of Population Health University of Adelaide ...
I → IIa
... suspected ACS for whom nitroglycerin [NTG] has been prescribed previously to take not more than 1 dose of NTG sublingually in response to chest discomfort/pain. If chest discomfort/pain is unimproved or is worsening 5 min after 1 NTG dose has been taken, it is recommended that the patient or family ...
... suspected ACS for whom nitroglycerin [NTG] has been prescribed previously to take not more than 1 dose of NTG sublingually in response to chest discomfort/pain. If chest discomfort/pain is unimproved or is worsening 5 min after 1 NTG dose has been taken, it is recommended that the patient or family ...
The little imitator-porphyria: a neuropsychiatric
... The estimated gene frequency of acute intermittent porphyria is 1-2 in 10 00020; however, there is great regional variability. The prevalence of variegate porphyria among the Afrikaans population of South Africa, where the introduction of the disorder has been traced back to a Dutch immigrant in 168 ...
... The estimated gene frequency of acute intermittent porphyria is 1-2 in 10 00020; however, there is great regional variability. The prevalence of variegate porphyria among the Afrikaans population of South Africa, where the introduction of the disorder has been traced back to a Dutch immigrant in 168 ...
prescribing information for INVOKAMET
... • Gradually escalate metformin dose to reduce the gastrointestinal side effects while not exceeding total daily dose of 2000 mg (2.1) • Assess renal function before initiating and periodically thereafter (2.2) • INVOKAMET is contraindicated in patients with an estimated glomerular filtration rate ( ...
... • Gradually escalate metformin dose to reduce the gastrointestinal side effects while not exceeding total daily dose of 2000 mg (2.1) • Assess renal function before initiating and periodically thereafter (2.2) • INVOKAMET is contraindicated in patients with an estimated glomerular filtration rate ( ...
A. INGREDIENT NAME: J)IMERCAPTO-1-PROPANEWLFONIC (DMPS) B. Chemical Name:
... times daily. It haa also been administered parenteralIy. Reviews. 1, Aposhgan HV. OMSA and OMPS—waler soluble antidotes for heavy metal poisoning. Ann Rev Phurmacol To.mc.l 1983; 23: ...
... times daily. It haa also been administered parenteralIy. Reviews. 1, Aposhgan HV. OMSA and OMPS—waler soluble antidotes for heavy metal poisoning. Ann Rev Phurmacol To.mc.l 1983; 23: ...
Cough Suppressant and Pharmacologic
... document. Finally, the scope of this section includes those drugs that have protussive effects (ie, any drug that may increase cough clearance) in patients with disorders in which thickened or accumulated mucus contributes to morbidity. In the previous evidence-based guideline, these types of cough ...
... document. Finally, the scope of this section includes those drugs that have protussive effects (ie, any drug that may increase cough clearance) in patients with disorders in which thickened or accumulated mucus contributes to morbidity. In the previous evidence-based guideline, these types of cough ...
Addressing the Unique Needs of Military Veterans With Chronic
... treatment to prevent the complications of cirrhosis, such as HCC. This will entail treating many patients before they develop cirrhosis. Timely diagnosis of HCV is the prerequisite to timely treatment, further underscoring the importance of birth cohort screening. The VHA has made considerable progr ...
... treatment to prevent the complications of cirrhosis, such as HCC. This will entail treating many patients before they develop cirrhosis. Timely diagnosis of HCV is the prerequisite to timely treatment, further underscoring the importance of birth cohort screening. The VHA has made considerable progr ...
Immune Globulin - Capital Blue Cross
... This policy addresses the use of human immune globulin therapy for preventing and/or treating a wide variety of disorders in the outpatient setting. Both intravenous infusion (IVIg) and subcutaneous infusion (SCIg) of immune globulin are addressed. However, the policy only considers nonspecific pool ...
... This policy addresses the use of human immune globulin therapy for preventing and/or treating a wide variety of disorders in the outpatient setting. Both intravenous infusion (IVIg) and subcutaneous infusion (SCIg) of immune globulin are addressed. However, the policy only considers nonspecific pool ...
new drugs,new devices and considerations for best practice
... Both will improve symptoms; LAMAs (tiotropium) may be superior in ↓ exacerbations (but unclear if this applies to newer agents). LAMAs may also be better tolerated than LABAs (↓ withdrawal in RCTs). Often in clinical practice, LAMAs are the preferred starting point. ...
... Both will improve symptoms; LAMAs (tiotropium) may be superior in ↓ exacerbations (but unclear if this applies to newer agents). LAMAs may also be better tolerated than LABAs (↓ withdrawal in RCTs). Often in clinical practice, LAMAs are the preferred starting point. ...
DIVALPROEX SODIUM DELAYED-RELEASE TABLETS
... receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a lo ...
... receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a lo ...
Rituxan Prescribing Information
... Standard Infusion: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr. For previously untreated follicular NHL and DLBCL patients: If patients did not experience a Grade 3 or 4 infusio ...
... Standard Infusion: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr. For previously untreated follicular NHL and DLBCL patients: If patients did not experience a Grade 3 or 4 infusio ...
Clinical Guideline: Management of Gastroparesis
... Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis ...
... Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis ...
Full Text - Avicenna Journal of Dental Research
... pylori interaction with surface epithelial cells develops direct cell damage or produces pro-inflammatory mediators (29). Secondly, H. pylori reaches the underlying mucosa, hence stimulates immune response, which in turn leads to liberation of different cytokines and oxygen radicals (30). The presen ...
... pylori interaction with surface epithelial cells develops direct cell damage or produces pro-inflammatory mediators (29). Secondly, H. pylori reaches the underlying mucosa, hence stimulates immune response, which in turn leads to liberation of different cytokines and oxygen radicals (30). The presen ...
Document
... Severe cardiac conduction disorders have seldom been reported after treatment with paclitaxel as a single agent. If patients develop clear cardiac conduction disorders during treatment with paclitaxel, suitable treatment should be initiated and the cardiac function monitored continuously during subs ...
... Severe cardiac conduction disorders have seldom been reported after treatment with paclitaxel as a single agent. If patients develop clear cardiac conduction disorders during treatment with paclitaxel, suitable treatment should be initiated and the cardiac function monitored continuously during subs ...
Pan London Cytotoxic Policy
... HEALTH AND SAFETY including exposure, handling and Personal Protective Equipment (PPE) ...
... HEALTH AND SAFETY including exposure, handling and Personal Protective Equipment (PPE) ...
![[product name]ô - Medicines.org.au](http://s1.studyres.com/store/data/008000412_1-46949def3934af5767510e4e0fa790d5-300x300.png)
[product name]ô - Medicines.org.au
... Long term therapy for the prevention of relapse (acute exacerbations) in chronic schizophrenic patients. The long term efficacy and tolerability of risperidone was established at the time of marketing in open long term studies involving 402 patients of whom 282 had been treated with risperidone for ...
... Long term therapy for the prevention of relapse (acute exacerbations) in chronic schizophrenic patients. The long term efficacy and tolerability of risperidone was established at the time of marketing in open long term studies involving 402 patients of whom 282 had been treated with risperidone for ...
AusPAR: Pomalidomide - Therapeutic Goods Administration
... For the treatment of MM in patients who have failed two or more prior therapies. The proposed indication is more restrictive, specifying the actual therapies that must be failed, and includes the use with low dose (LD) dexamethasone. At the time of the Australian submission to the TGA, three other r ...
... For the treatment of MM in patients who have failed two or more prior therapies. The proposed indication is more restrictive, specifying the actual therapies that must be failed, and includes the use with low dose (LD) dexamethasone. At the time of the Australian submission to the TGA, three other r ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.